Journal article

Automation of CAR-T cell adoptive immunotherapy bioprocessing: Technology opportunities to debottleneck manufacturing

Abstract:: Continued clinical efficacy demonstrations of cell-based immunotherapies (iTx) such as chimeric antigen receptor T cell (CAR-T) therapies has made the prospect increasingly likely of an immunotherapy product achieving conditional market authorization in the short term.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Bure, K., Ball, A., Biagioni, K., Mehta, S., Choudhary, R., Arshad, Z., Pettitt, D., Holländer, G., Al-Mossawi, H., Faulstich, F., Reeve, B., Smith, J., & Brindley, D. (2016). Automation of CAR-T cell adoptive immunotherapy bioprocessing: Technology opportunities to debottleneck manufacturing. BioProcess International.

MLA Style

Bure, K, et al. “Automation of CAR-T Cell Adoptive Immunotherapy Bioprocessing: Technology Opportunities to Debottleneck Manufacturing.” BioProcess International, 2016.

Chicago Style

Bure, K, A Ball, K Biagioni, et al. 2016. “Automation of CAR-T Cell Adoptive Immunotherapy Bioprocessing: Technology Opportunities to Debottleneck Manufacturing.” BioProcess International.
Print

Authors

+ Bure, K More by this author

Role:: Author

+ Ball, A More by this author

Role:: Author

+ Biagioni, K More by this author

Role:: Author

+ Mehta, S More by this author

Role:: Author

+ Choudhary, R More by this author

Role:: Author

More authors...

+ SENS Research Foundation More from this funder

Funding agency for:: Brindley, D

+ Saïd Foundation More from this funder

Funding agency for:: Brindley, D

+ Oxford Musculoskeletal National Institute for Health Research More from this funder

Funding agency for:: Brindley, D

+ CASMI Translational Stem Cell Consortium More from this funder

Publisher:: BioProcess International
Journal:: BioProcess International More from this journal
Publication date:: 2016-04-18
Acceptance date:: 2016-01-01
EISSN:: 1945-7065
ISSN:: 1542-6319

Keywords:: Journal Article
Pubs id:: pubs:626356
UUID:: uuid:9d4bec59-7310-4a8f-95c1-e66ce618dbc2
Local pid:: pubs:626356
Source identifiers:: 626356
Deposit date:: 2016-10-04
ARK identifier:: ark:/29072/ora_9d4bec5973104a8f95c1e66ce618dbc2

Terms of use

Copyright holder:: BioProcess International
Copyright date:: 2016
Notes:: © BioProcess International.

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP